Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.58 |
| ▸ | ROCK1 | Q13464 | 13/20 | 0.55 |
| ▸ | BCL6 | P41182 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA6 | P23280 | 1/20 | 0.54 |
| ▸ | CA5A | P35218 | 1/20 | 0.54 |
| ▸ | CA7 | P43166 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.54 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.54 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.54 |
| ▸ | HTR3B | O95264 | 1/20 | 0.54 |
| ▸ | HTR3A | P46098 | 1/20 | 0.54 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.54 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.54 |
| ▸ | CDC7 | O00311 | 1/20 | 0.53 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5306034 | 0.88 | ROCK1 (0.55) | ROCK1BCL6CA12CA1CA2 | |
| SCHEMBL2959707 | 0.82 | ROCK1 (0.61) | ROCK1BCL6CA12CA1CA2 | |
| SCHEMBL16380594 | 0.82 | ROCK2 (0.58) | ROCK1BCL6CA12CA1CA2 | |
| SCHEMBL5308695 | 0.79 | ROCK1 (0.61) | ROCK1BCL6CA12CA1CA2 | |
| SCHEMBL29645150 | 0.78 | ROCK1 (0.69) | ROCK1BCL6CA12CA1CA2 | |
| SCHEMBL11166939 | 0.77 | ROCK1 (0.55) | ROCK1BCL6CA12CA1CA2 | |
| SCHEMBL3044185 | 0.77 | KDR (0.58) | KDRKCNH2SCN9A | |
| SCHEMBL29645155 | 0.76 | ROCK1 (0.68) | ROCK1BCL6HTR3EHTR3BHTR3A | |
| SCHEMBL27612768 | 0.76 | SYK (0.70) | KDRROCK1BCL6HTR3EHTR3B | |
| SCHEMBL14404598 | 0.74 | MAPKAPK2 (0.69) | ROCK1CA12CA1CA2CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240327383-A1 | PIPERIDINE DERIVATIVE, AND PHARMACEUTIAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | Yichang Humanwell Pharmaceutical Co., Ltd. (CN) | 2024-10-03 | — | — | US | disclosed |
| EP-4345096-A1 | PIPERIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | Yichang Humanwell Pharmaceutical Co., Ltd. (CN) | 2024-04-03 | — | — | EP | disclosed |
| EP-3495341-B1 | PREPARATION PROCESS OF PERFLUOROALKYL COMPOUND WITH MONOHYDROPERFLUOROALKANE AS STARTING MATERIAL | KANTO DENKA KOGYO KK (JP) | 2022-11-02 | — | — | EP | disclosed |
| US-10450253-B2 | Preparation process of perfluoroalkyl compound with monohydroperfluoroalkane as starting material | KANTO DENKA KOGYO CO., LTD. (JP) | 2019-10-22 | — | — | US | disclosed |
| EP-3495341-A1 | METHOD FOR PRODUCING PERFLUOROALKYL COMPOUND USING MONOHYDROPERFLUOROALKANE AS STARTING MATERIAL | Kanto Denka Kogyo Co., Ltd. (JP) | 2019-06-12 | — | — | EP | disclosed |
| US-20190169107-A1 | PREPARATION PROCESS OF PERFLUOROALKYL COMPOUND WITH MONOHYDROPERFLUOROALKANE AS STARTING MATERIAL | NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITY (JP) | 2019-06-06 | — | — | US | disclosed |
| US-9018209-B2 | Compounds and methods for the treatment of viruses and cancer | YALE UNIVERSITY (US) | 2015-04-28 | — | — | US | disclosed |
| US-20100222352-A1 | Compounds and Methods for the Treatment of Viruses and Cancer | YALE UNIVERSITY (US) | 2010-09-02 | — | — | US | disclosed |
| US-20100222386-A1 | SUBSTITUTED PIPERIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | US | disclosed |
| US-7767695-B2 | Substituted piperidines | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-08-03 | — | — | US | disclosed |
| EP-1434765-B1 | SUBSTITUTED PIPERIDINES WITH SELECTIVE BINDING TO HISTAMINE H3-RECEPTOR | HIGH POINT PHARMACEUTICALS LLC (US) | 2009-12-02 | — | — | EP | disclosed |
| WO-2007038387-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OF VIRUSES AND CANCER | YALE UNIVERSITY (US) | 2007-04-05 | — | — | WO | disclosed |
| US-20040248938-A1 | such as 2-Biphenyl-4-yl-N-methyl-N-(1-methylpiperidin-4-yl)acetamide hydrochloride, used as histamine H3 receptor antagonist or agonists; antidiabetic, hypotensive or hypoglycemic agents | HIGH POINT PHARMACEUTICALS, LLC | 2004-12-09 | — | — | US | disclosed |
| US-20030186963-A1 | Substituted piperidines | NOVO NORDISK A/S (DK) | 2003-10-02 | — | — | US | disclosed |
| US-5786481-A | 3-THIO-7-AZABICYCLO(3.3.1)NONANES FOR CARDIOVASCULAR DISORDERS | THE BOARD OF REGENTS, OKLAHOMA STATE UNIVERSITY (US) | 1998-07-28 | — | — | US | disclosed |
| US-5468858-A | Sudden death syndrome | THE BOARD OF REGENTS OF OKLAHOMA STATE UNIVERSITY PHYSICAL SCIENCES (US) | 1995-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186963-A1 | Substituted piperidines | HRH3, HRH4, HRH2 | KDR 2367/4885ROCK1 4459/4885BCL6 2330/4885 |
| US-20240327383-A1 | PIPERIDINE DERIVATIVE, AND PHARMACEUTIAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | OPRL1, OPRD1, OPRM1 | KDR 489/4885ROCK1 958/4885BCL6 4207/4885 |
| US-20100222386-A1 | SUBSTITUTED PIPERIDINES | HRH3, HRH4, HRH2 | KDR 2367/4885ROCK1 4459/4885BCL6 2330/4885 |
| US-20040248938-A1 | such as 2-Biphenyl-4-yl-N-methyl-N-(1-methylpiperidin-4-yl)acetamide hydrochloride, used as histamine H3 receptor antagonist or agonists; antidiabetic, hypotensive or hypoglycemic agents | HRH3, HRH4, HRH2 | KDR 637/4885ROCK1 2908/4885BCL6 2921/4885 |
| US-20190169107-A1 | PREPARATION PROCESS OF PERFLUOROALKYL COMPOUND WITH MONOHYDROPERFLUOROALKANE AS STARTING MATERIAL | PFKFB1, PFKFB4, PFAS | KDR 589/4885ROCK1 1704/4885BCL6 1243/4885 |
| US-20100222352-A1 | Compounds and Methods for the Treatment of Viruses and Cancer | RCOR1, RCOR3, CCNT1 | KDR 1458/4885ROCK1 1934/4885BCL6 52/4885 |
| US-10450253-B2 | Preparation process of perfluoroalkyl compound with monohydroperfluoroalkane as starting material | PFKFB1, PFKFB4, PFAS | KDR 589/4885ROCK1 1704/4885BCL6 1243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.